EP4090686A4 - Pro-anticorps réduisant la toxicité hors cible - Google Patents

Pro-anticorps réduisant la toxicité hors cible Download PDF

Info

Publication number
EP4090686A4
EP4090686A4 EP21741991.0A EP21741991A EP4090686A4 EP 4090686 A4 EP4090686 A4 EP 4090686A4 EP 21741991 A EP21741991 A EP 21741991A EP 4090686 A4 EP4090686 A4 EP 4090686A4
Authority
EP
European Patent Office
Prior art keywords
pro
antibody
reduces
target toxicity
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21741991.0A
Other languages
German (de)
English (en)
Other versions
EP4090686A2 (fr
Inventor
Kuo-Fu TSENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunelogic Therapeutics Inc
Original Assignee
Immune Targeting Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Inc filed Critical Immune Targeting Inc
Priority claimed from PCT/US2021/013688 external-priority patent/WO2021146590A2/fr
Publication of EP4090686A2 publication Critical patent/EP4090686A2/fr
Publication of EP4090686A4 publication Critical patent/EP4090686A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21741991.0A 2020-01-17 2021-01-15 Pro-anticorps réduisant la toxicité hors cible Pending EP4090686A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062962555P 2020-01-17 2020-01-17
PCT/US2021/013688 WO2021146590A2 (fr) 2020-01-17 2021-01-15 Pro-anticorps réduisant la toxicité hors cible

Publications (2)

Publication Number Publication Date
EP4090686A2 EP4090686A2 (fr) 2022-11-23
EP4090686A4 true EP4090686A4 (fr) 2024-03-27

Family

ID=82906067

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21741991.0A Pending EP4090686A4 (fr) 2020-01-17 2021-01-15 Pro-anticorps réduisant la toxicité hors cible

Country Status (2)

Country Link
EP (1) EP4090686A4 (fr)
CN (1) CN114945597A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597753B2 (en) * 2020-04-30 2023-03-07 Immune Targeting, Inc. Activatable IL2 composition and methods of use
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (fr) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Protéines de liaison inductibles et méthodes d'utilisation
WO2019051102A2 (fr) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Protéines de liaison à activation conditionnelle restreinte

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP2015502397A (ja) * 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN104540518A (zh) * 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
CA2925106C (fr) * 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Substrats pour metalloproteinases matricielles et autres fragments clivables et leurs procedes d'utilisation
JP7020909B2 (ja) * 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
EP3778640A1 (fr) * 2015-05-01 2021-02-17 Genentech, Inc. Anticorps anti-cd3 masqués et leurs procédés d'utilisation
WO2016210447A1 (fr) * 2015-06-26 2016-12-29 University Of Southern California Lymphocytes t récepteurs antigéniques chimériques de masquage pour l'activation spécifique d'une tumeur
US11466093B2 (en) * 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
EP3465221B1 (fr) * 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
WO2018165619A1 (fr) * 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Anticorps de cd147, anticorps activables de cd147 et procédés associés de fabrication et d'utilisation
US11364303B2 (en) * 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
JPWO2020246563A1 (fr) * 2019-06-05 2020-12-10
WO2021195472A1 (fr) * 2020-03-26 2021-09-30 Aetio Biotherapy, Inc. Protéines de fusion bispécifiques pour la déplétion de lymphocytes t régulateurs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (fr) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Protéines de liaison inductibles et méthodes d'utilisation
WO2019051102A2 (fr) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Protéines de liaison à activation conditionnelle restreinte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANG SHANSHAN ET AL: "LegoBody: facile generation of bispecific and multi-specific antibodies", BIORXIV, 27 December 2019 (2019-12-27), XP093129094, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2019.12.25.888586v1.full.pdf> [retrieved on 20240208], DOI: 10.1101/2019.12.25.888586 *

Also Published As

Publication number Publication date
EP4090686A2 (fr) 2022-11-23
CN114945597A (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
CA3259367A1 (en) Pro-antibody that reduces off-target toxicity
EP4090686A4 (fr) Pro-anticorps réduisant la toxicité hors cible
EP4114375A4 (fr) Inhibiteurs de ferroptose-diarylamine para-acétamides
AU2021901309A0 (en) Tr3k board
AU2021901191A0 (en) Tre3k board
EM86542970003S (fr) Tiroirs
EM86542970004S (fr) Tiroirs
EM86542970002S (fr) Tiroirs
EM86542970001S (fr) Tiroirs
HK40109356A (en) Patch-pump
EM87738570001S (fr) Cibles multi-sports
AU2021904122A0 (en) Playsafe
AU2021903826A0 (en) Iceglass
EM87739800002S (fr) Hoverboards
EM87539090001S (fr) Veilleuses [lampes]
EM87400130001S (fr) Coquetiers
EM87370920001S (fr) Montres intelligentes
AU2021903423A0 (en) Easy-Grab
EM87231910034S (fr) Gilets
EM87219890001S (fr) Chauffe-mains [vêtements]
AU2021902982A0 (en) P1565au03
AU2021902800A0 (en) Enviro-lid-catch
EM86372680001S (fr) Marchepieds [escabeaux]
EM85771000001S (fr) Signets
EM85472440001S (fr) Couteaux de poche

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNE TARGETING INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20240227

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/58 20060101ALI20240221BHEP

Ipc: A61P 37/02 20060101ALI20240221BHEP

Ipc: A61P 17/06 20060101ALI20240221BHEP

Ipc: A61P 35/00 20060101ALI20240221BHEP

Ipc: C07K 16/30 20060101AFI20240221BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNELOGIC THERAPEUTICS, INC.